"Self-paying patients can buy the pill for $5 (3.70) a day, or $149 a month, for the starting dose of 1.5mg. Apart from being more affordable, the new version is expected to have wider appeal by being needle free and easier for the patient to fit into their routine. The 4mg dose will also be available for $149 a month until 15 April, then $199, while the highest doses cost $299 a month. Patients with insurance pay from $25 a month."
"Novo Nordisk's share price rose by more than 4% on Monday on news of the launch, but is still down by 44% over the past year amid fierce competition from US rival Eli Lilly's jabs Mounjaro and Zepbound. The Danish company, once the most valuable in Europe, hopes the pill will help it claw back market share after it issued several profit warnings, cut thousands of jobs and appointed new management last year."
"Matt Weston, a pharmaceutical analyst at UBS, said the price was lower than expected. US list prices for weight-loss jabs are about $1,000 a month or more, although Novo Nordisk started selling its Wegovy injection at $349 a month to cash payers in November. Both Novo and Eli Lilly have reduced prices of their jabs for people buying them for cash, rather than using health insurance."
Novo Nordisk launched the once-daily Wegovy pill in the US after recent regulatory approval, offering a needle-free GLP-1 option to treat obesity. Self-paying patients can purchase the starting 1.5mg dose for $5 a day or $149 a month, with higher doses priced up to $299 a month and insured patients paying from $25 monthly. The pill aims to broaden appeal by being easier to integrate into routines and more affordable than many injectable alternatives. The launch boosted Novo Nordisk's share price, intensified competition with Eli Lilly, and could affect market share and pricing dynamics in the obesity drug market.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]